Date: 2017-11-08
Type of information: IPO
Company: InflaRX (Germany)
Investors:
Amount: $100 million
Funding type: IPO
Planned used:
Others:
- • On November 8, 2017, InflaRx announced the pricing of its initial public offering of 6,667,000 common shares at an initial public offering price of $15.00 per common share, for total gross proceeds of approximately $100 million. In addition, InflaRx has granted the underwriters a 30-day option to purchase up to an additional 1,000,050 common shares at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by InflaRx. The shares are scheduled to begin trading on the NASDAQ Global Select Market on November 8, 2017 under the ticker symbol “IFRX.” The offering is expected to close on November 10, 2017, subject to customary closing conditions.
- J.P. Morgan, Leerink Partners and BMO Capital Markets are acting as joint book-running managers for the offering.
Therapeutic area: Inflammatory diseases
Is general: Yes
